ClinicalTrials.gg
Status unknownNCT03554031Updated Jun 12, 2018

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome

A Phase 3 interventional study of Recombinant Human Growth Hormone (rhGH) Injection in Prader-Willi Syndrome, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Status unknown at 6 sites in China. Open to participants aged 1 Month to 5 Years. Per ClinicalTrials.gov, last updated 2018-06-12.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
1 Month to 5 Years
Sex
All
01

Study summary

To evaluate the effectiveness of rhGH (Recombinant human growth hormone) injection for improving motor development in patients with PWS.

02

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

03

In context

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

This study's planned enrollment of 30 is close to the median of 30 across 100 interventional studies indexed under Prader-Willi Syndrome.

Browse Prader-Willi Syndrome studies →

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Signed from legal guardian of the subjects;
  • Subjects are willing and able to cooperate to complete scheduled visits, treatment plans and laboratory tests and other procedures;
  • Diagnosed as PWS by gene test;
  • Age: 1 month (30 days after birth) - 5 years of age;
  • Male or female;
  • Calculated by Peabody Developmental Motor Scale, total motor quotient, gross motor quotient or fine motor quotient is less than 90 points;
  • Thyroid function is within the normal reference range or remained within the normal reference range by substitution therapy;
  • No history of rhGH therapy before.

Exclusion criteria

Exclusion Criteria:

  • Subjects with abnormal liver or kidney function;
  • Subjects with obvious central sleep apnea and/or moderate or severe obstructive sleep apnea, acute lung infection;
  • Subjects with chronic diseases that have long-term effects on bone metabolism and body composition;
  • Subjects with congenital skeletal dysplasia, or spine scoliosis with moderate and above degree requiring treatment or lameness;
  • Subjects with history of congenital heart disease, or an echocardiogram showing that the structural abnormalities require surgery or interventional therapy or that the is \<40%, or the abnormal requiring intervention;
  • Subjects with history of convulsions or epilepsy;
  • Subjects with other systemic chronic diseases;
  • Subjects with diagnosed tumors;
  • Subjects with family history of cancers, a previous history of cancer, or considered to be a high risk of cancer combinating other information;
  • Subjects with mental disease;
  • Subjects with diabetes, or abnormal fasting glucose and researchers believe that may affect the safety of the subject;
  • Subjects with severe obesity;
  • Subjects with highly allergic constitution or allergy to proteins or product or its ;
  • Subjects who took part in other clinical trials within 3 months ;
  • Subjects who received drug treatment that may interfere with GH secretion or GH action within 3 months;
  • Other conditions in which the investigator preclude enrollment into the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    rhGH injection/Jintropin AQ

    Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.No control.

    Drug: Recombinant Human Growth Hormone (rhGH) Injection

Interventions

  • Drug: Recombinant Human Growth Hormone Injection /Jintropin AQ, 30IU/10 mg/3ml/kit, 0.5 mg/m2/d for the first 4 weeks, then 1.0 mg/m2/d for subsequent 48 weeks; by subcutaneous injection, once per day for total 52 weeks.

06

What researchers measure

Primary outcomes

  1. The change of the total motor quotient calculated by Peabody Developmental Motor Scale before and after treatment

    Time frame: Baseline, 26 weeks, 52 weeks

Secondary outcomes

  1. Gross motor quotient and fine motor quotient calculated by Peabody Developmental Motor Scale before and after treatment

    Time frame: Baseline, 26 weeks, 52 weeks

  2. Change of height standard deviation score (SDS) by chronological age before and after treatment

    Time frame: Baseline, 4 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks

  3. Body weight change before and after treatment

    Time frame: Baseline, 4 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks

  4. Change of BMI (Body mass index) standard deviation score before and after treatment

    Time frame: Baseline, 4 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks

  5. Global quotient, locomotor quotient, personal-social development quotient, language quotient, eye and hand coordination quotient, performance quotient and practical reasoning change calculated by Griffiths Mental Development Scale

    Time frame: Baseline, 26 weeks, 52 weeks

  6. Bone maturation ( bone age/ chronological age: BA/CA)

    Time frame: Baseline, 52 weeks

  7. Change of IGF-1(Insulin-like growth factor 1) SDS

    Time frame: Baseline, 4 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks

  8. IGF-1/IGFBP-3 molar ratio

    Time frame: Baseline, 4 weeks, 13 weeks, 26 weeks, 39 weeks, 52 weeks

07

Study locations

6 of 6 sites recruiting
  • Tongji medical college huazhong university of science & technology
    Wuhan, Hubei, China
    Recruiting
  • The Children's Hospital,Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
  • Beijing Children's Hospital, Capital Medical University
    Beijing, China
    Recruiting
  • Peking union medical college hospital
    Beijing, China
    Recruiting
  • Peking university first hospital
    Beijing, China
    Recruiting
  • Children's Hospital of Fudan University
    Shanghai, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2018 (actual). Primary completion is estimated for Jan 2020, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2018
First posted
Jun 12, 2018
StartActual
Apr 14, 2018
Primary completionEst.
Jan 2020
CompletionEst.
Jan 1, 2020
Last update
Jun 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03554031
Collaborators
Children's Hospital of Fudan University, Tongji medical college huazhong university of science & technology, Beijing Children's Hospital, Peking University First Hospital, Peking Union Medical College Hospital, The Children's Hospital of Zhejiang University School of Medicine
Responsible party
Sponsor
First posted
Jun 12, 2018
Start date
Apr 14, 2018
Primary completion
Jan 2020 (estimated)
Completion
Jan 1, 2020 (estimated)
Last update
Jun 12, 2018

Study contacts

Xiaohua Feng
Contact
fengxiaohua@gensci-china.com
0431-85170552
Feihong Luo, Doctor
principal investigator · Children's Hospital of Fudan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion